Johnson & Johnson Submits An FDA Application For Fixed Combination Of Amivantamab And Recombinant Human Hyaluronidase For Subcutaneous Administration For All Currently Approved Or Submitted Indications Of IV Rybrevant In Certain Type Of NSCLC
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has submitted an FDA application for a fixed combination of Amivantamab and Recombinant Human Hyaluronidase for subcutaneous administration. This combination is intended for all currently approved or submitted indications of IV Rybrevant in certain types of non-small cell lung cancer (NSCLC).
June 17, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson has submitted an FDA application for a new subcutaneous combination treatment for NSCLC, which could expand the use of Rybrevant.
The submission of an FDA application for a new treatment option could potentially expand the market for Rybrevant, leading to increased revenues for Johnson & Johnson. This is a positive development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100